Chidamide treatment led to remarkable downregulation of HMGB1 expression at both mRNA and protein levels (Fig. 5c, d), with concomitantly increased TGFBI expression in the partial AML samples (Fig. S1). The gene discussed is HMGB1; the disease is acute myeloid leukemia.